Incidence and management of venous thromboembolism in patients with glioblastoma: a retrospective single-center analysis

Clicks: 3
ID: 323464
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #241 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction Glioblastoma (GBM) is associated with a prothrombotic state, directly associated with the production of the potent procoagulant, tissue factor (TF), significantly increasing the risk of venous thromboembolism (VTE). The risk of intracranial hemorrhage with the use of anticoagulants complicates the management of VTE in patients with brain tumor. These complications pose a challenge in clinical management, balancing the risk of hemorrhage with the need for anticoagulation or mechanical filtration. Furthermore, this group of tumors is usually excluded from most studies. Purpose To evaluate the incidence, distribution, therapeutic management, and timing of thrombotic events in a large cohort of patients with glioblastoma treated at a specialized neurological center in a South American country. Methods We conducted a retrospective descriptive study of 641 patients diagnosed with glioblastoma. Patients were categorized based on the presence and type of thrombotic event: no thrombosis, infrapatellar deep vein thrombosis (DVT), suprapatellar DVT, pulmonary embolism (PE), and cerebral venous thrombosis (CVT)/other. Treatment modalities and the mean time from the first surgery to the thrombotic event were analyzed. Results Out of 641 patients, 448 (69.9%) did not experience thrombotic events. Thrombosis occurred in 193 patients (30.1%), with a mean time from surgery to event of 162 days. Enoxaparin was the primary treatment (71.5%), followed by inferior vena cava (IVC) filters (23.3%). Events were distributed as follows: Infrapatellar DVT: 90 patients (14.0%). Management: enoxaparin (n=66, 73.3%), IVC filter (n=21, 23.3%), others (n=3). Mean time to event: 98 days. Suprapatellar DVT: 40 patients (6.2%). Management: enoxaparin (n=25, 62.5%), IVC filter (n=14, 35.0%), acenocoumarol (n=1). Mean time to event: 270 days. Pulmonary Embolism: 56 patients (8.7%). Management: enoxaparin (n=43, 76.8%), IVC filter (n=10, 17.9%), thrombectomy (n=2), surveillance (n=1). Mean time to event: 184 days. CVT/Other: 7 patients (1.1%). Management: enoxaparin (n=4), surveillance (n=1), TBD (n=2). Mean time to event: 192 days. Conclusions The incidence of VTE in this GBM population was approximately 30%. Distal (infrapatellar) DVT was the most frequent presentation and occurred earliest (mean 98 days), whereas proximal DVT occurred significantly later (mean 270 days). While low molecular weight heparin was the standard of care, nearly a quarter of thrombotic patients required IVC filters. Given the high incidence of thrombosis in this subpopulation, further studies are warranted to identify patients at highest risk and to define whether prophylactic strategies offer a benefit that outweighs the known risk of bleeding.Table 1 Graphic 1
Reference Key
openalex_W7172261122 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors F Bordon Orsingher, N Zareba, F Bursztyn, N Perez Bertana, F Mazzitelli, J C Salas, J Mercado, R Delorme, F Capparelli, N Wainsztein, J J Herrera Paz, B Calabrese, S Cerrato, A Muggeri, C Galmarini
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.168
URL
https://doi.org/10.1093/eurheartjsupp/suag097.168
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.